RxDoctor Payments DataLook up a doctor →

David Konanc, MD

Neurology · Raleigh, NCNPI 1801842794

Payments from drug & device makers

$250,894in general payments, 2019–2025

Across 745 payments — averaging $336.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$231K
  • Janssen Research & Development, LLC$6K
  • AbbVie$1K
  • AstraZeneca$907
  • Novartis$895
  • Neurocrine Biosciences, Inc.$603
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$1151%
  • Food & beverage$12,51396%
  • Education$2332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.40$231,389
Janssen Research & Development, LLC5$6,494
AbbVie(2 entities)77$1,302
AstraZeneca(2 entities)37$907
Novartis55$895
Neurocrine Biosciences, Inc.35$603
MDD US Operations, LLC41$542
UCB, Inc.23$478
Biogen18$442
Sanofi17$429
Genentech USA, Inc.23$421
Lilly USA, LLC29$417
TG Therapeutics, Inc.14$386
Amgen20$369
Argenx US, Inc.15$368
Eisai Inc.12$299
Teva Pharmaceuticals USA, Inc.18$289
Lundbeck LLC11$263
Neurelis, Inc.13$262
CSL Behring12$228
Johnson & Johnson12$219
EMD Serono, Inc.14$218
Merz Pharmaceuticals, LLC9$205
Pfizer13$203
Avion Pharmaceuticals10$192
Acorda Therapeutics, Inc13$192
Grifols USA, LLC8$165
Sunovion Pharmaceuticals Inc.10$152
SK Life Science, Inc.7$148
Avanir Pharmaceuticals, Inc.8$147
Amneal Pharmaceuticals LLC7$137
Bristol Myers Squibb7$124
Arbor Pharmaceuticals, Inc.7$118
Ipsen Biopharmaceuticals, Inc6$112
Jazz Pharmaceuticals Inc.5$99
Takeda Pharmaceuticals U.S.A., Inc.4$95
Impel Pharmaceuticals Inc.5$92
Kyowa Kirin, Inc.4$81
Acadia Pharmaceuticals Inc5$71
Merz North America, Inc.2$70
Assertio Therapeutics, Inc.5$68
Catalyst Pharmaceuticals, Inc.3$65
GRT US Holding, Inc.3$57
Adamas Pharmaceuticals, Inc.4$57
Microtransponder, Inc.3$56
Harmony Biosciences LLC2$55
Collegium Pharmaceutical, Inc.3$52
GE HealthCare4$50
Tanabe Pharma America, Inc.2$49
Bausch Health US, LLC3$49
Aquestive Therapeutics, Inc.3$46
Impel Pharmaceuticals LLC2$44
Mallinckrodt Enterprises LLC3$42
Aucta Pharmaceuticals, Inc.3$40
Otsuka America Pharmaceutical, Inc.2$33
Idorsia Pharmaceuticals US Inc2$32
Supernus Pharmaceuticals, Inc.2$30
Revance Therapeutics, Inc.1$28
Promius Pharma LLC2$28
Livanova USA, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$250,894 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,309,306
Medicare patients
473
Services billed
90,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate14$69,965
AustedoDeutetrabenazine12$64,780
Nurtec OdtRimegepant Sulfate46$45,971
RytaryCarbidopa/Levodopa16$26,451
NourianzIstradefylline11$24,420
Emgality PenGalcanezumab-Gnlm25$23,283
Aimovig AutoinjectorErenumab-Aooe21$14,973
Dalfampridine ErDalfampridine24$13,726
Lacosamide27$10,002
Levetiracetam152$5,632
Chlorpromazine Hcl12$5,111
Memantine Hcl191$4,961
Gabapentin277$3,937
Carbidopa-LevodopaCarbidopa/Levodopa161$3,921
Carbamazepine ErCarbamazepine22$3,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$71$69,96514 claims
Teva Pharmaceuticals USA, Inc.Austedo$289$64,78012 claims
PfizerNurtec Odt$203$45,97146 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$137$28,15041 claims
Kyowa Kirin, Inc.Nourianz$81$24,42011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 566 neurology providers in North Carolina.

Other neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →